Epigenome Editing: Emerging Tools, Therapeutic Applications, and Challenges in Human Disease Treatment

Epigenetic modifications, including histone alterations, non-coding RNA interactions, and DNA methylation, regulate gene expression without altering the underlying DNA sequence. These modifications are essential for normal biological processes; however, their aberrant regulation is linked to numerous life-threatening disorders. Genome editing nucleases such as zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and CRISPR/Cas systems offer promising tools for the precise correction of epigenetic abnormalities. This review explores epigenetic mechanisms, genome editing technologies for epigenetic modulation, and their applications in disease contexts, such as cancer and neurodegeneration, with reference to both in vitro and in vivo studies demonstrating therapeutic potential. For instance, aberrant histone acetylation and methylation patterns are frequently observed in cancer. Abnormal DNA methylation and disruptions in histone modifications have been implicated in neurological disorders, such as Alzheimer’s and Huntington’s disease. Although ZFNs and TALENs are foundational tools, their use has been limited by challenges in protein engineering and nonspecific targeting. CRISPR/Cas systems have become a versatile platform. Catalytically inactive Cas9 (dCas9) can be fused to epigenetic editing domains, such as histone deacetylases and DNA methyltransferases, to precisely regulate gene expression. For example, dCas9 has been used to reactivate the BRCA1 tumor suppressor gene in cancer cells. Although epigenetic editing holds significant promise in biomedical research and precision medicine, several challenges remain. These include unintended epigenetic alterations, the efficient delivery of editing tools to target cells, and limited in vivo validation. Future studies using animal models are essential to evaluate the translational potential and clinical applicability of this approach.

Authors

Institutions

Publication Details

Journal
Biotech Studies
Published
2026-01-04
DOI
https://doi.org/10.38042/biotechstudies.1830114
Primary Topic
CRISPR and Genetic Engineering
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Epigenome Editing: Emerging Tools, Therapeutic Applications, and Challenges in Human Disease Treatment

Maryam Mirahmadi, Sayed Hassan Tabatabaee, Yong Teng, Forough Shams et al.
Biotech Studies
CRISPR and Genetic Engineering
article

Epigenome Editing: Emerging Tools, Therapeutic Applications, and Challenges in Human Disease Treatment

Maryam Mirahmadi, Sayed Hassan Tabatabaee, Yong Teng, Forough Shams, Azam Rahimpour, Nader Hashemi
article en

Abstract

Epigenetic modifications, including histone alterations, non-coding RNA interactions, and DNA methylation, regulate gene expression without altering the underlying DNA sequence. These modifications are essential for normal biological processes; however, their aberrant regulation is linked to numerous life-threatening disorders. Genome editing nucleases such as zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and CRISPR/Cas systems offer promising tools for the precise correction of epigenetic abnormalities. This review explores epigenetic mechanisms, genome editing technologies for epigenetic modulation, and their applications in disease contexts, such as cancer and neurodegeneration, with reference to both in vitro and in vivo studies demonstrating therapeutic potential. For instance, aberrant histone acetylation and methylation patterns are frequently observed in cancer. Abnormal DNA methylation and disruptions in histone modifications have been implicated in neurological disorders, such as Alzheimer’s and Huntington’s disease. Although ZFNs and TALENs are foundational tools, their use has been limited by challenges in protein engineering and nonspecific targeting. CRISPR/Cas systems have become a versatile platform. Catalytically inactive Cas9 (dCas9) can be fused to epigenetic editing domains, such as histone deacetylases and DNA methyltransferases, to precisely regulate gene expression. For example, dCas9 has been used to reactivate the BRCA1 tumor suppressor gene in cancer cells. Although epigenetic editing holds significant promise in biomedical research and precision medicine, several challenges remain. These include unintended epigenetic alterations, the efficient delivery of editing tools to target cells, and limited in vivo validation. Future studies using animal models are essential to evaluate the translational potential and clinical applicability of this approach.

Biotech Studies(35)
Georgia Institute of Technology (US), Emory University (US), Tarbiat Modares University (IR), University of Tehran (IR), Cancer Institute (WIA) (IN), The Wallace H. Coulter Department of Biomedical Engineering (US), Shahid Beheshti University of Medical Sciences (IR)
Shahid Beheshti University of Medical Sciences
Openalex Percentile: Top 98%
CRISPR and Genetic Engineering
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.